Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2529PDF: 1956HTML: 1097 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3589PDF: 1706HTML: 4103 -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
5249PDF: 3042HTML: 2389 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
3535PDF: 1044HTML: 4994 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2733PDF: 934HTML: 9086Efremov 1: 287Efremov 2: 259 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
3130PDF: 1123HTML: 5681 -
TYROSINE KINASE INHIBITORS AND INTERFERON
3066PDF: 1547HTML: 3107Cover Letter: 283 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1949PDF: 1283HTML: 375 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
4250PDF: 1671HTML: 9334Untitled: 360Untitled: 238Untitled: 226Untitled: 242Untitled: 237Untitled: 406 -
A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA
3382PDF: 1463HTML: 4171 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1778HTML: 731PDF: 935 -
THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2433PDF: 963HTML: 2038Fig 1 Rossi: 263 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
3094PDF: 1372HTML: 2856Figure 1: 238 -
TYROSINE KINASE INHIBITORS AND PREGNANCY
3930PDF: 1820HTML: 2785 -
PATHOGENESIS AND TREATMENT OF THROMBOHEMORRHAGIC DIATHESIS IN ACUTE PROMYELOCYTIC LEUKEMIA
2052PDF: 919HTML: 10379Figures 1,2,3: 336 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1665PDF: 1045HTML: 277 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2458PDF: 1144HTML: 2041Characteristic of study group: 276 -
DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia
1665PDF: 1360HTML: 548 -
DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE
277958PDF: 1924HTML: 3919 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2536PDF: 1420HTML: 17252Bassan Fig.1: 190Bassan Fig.2: 296Bassan Fig.4: 178Fig.3: 320 -
CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY
4513PDF: 2066HTML: 5577Table 1: 315 -
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES. Hematopoietic stem cell transplatation in the elderly fo Acute Myeloid Leukemia
1949PDF: 584HTML: 377 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
2058PDF: 1272HTML: 358 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
4033PDF: 1804HTML: 11991Figures Haase: 315 -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL
1841PDF: 1180HTML: 201 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
2528PDF: 678HTML: 393 -
POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.
1296PDF: 685Suppl. Files: 159HTML: 554 -
LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
1856PDF: 883HTML: 936jdoe, table 2 infections CML .doc: 263jdoe, table 1 infections CML .doc: 238 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
650PDF: 323HTML: 164







